Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe?

The administration of drugs acting on the immune system in order to improve the body’s ability to recognize and destroy cancer cells is really changing the history of lung cancer. In the pre-immunotherapy era, only 5.5% of patients with advanced non-small cell lung cancer (NSCLC) were alive 5 years after diagnosis and the majority of these patients did not exceed the year (1).